Trial · NCT07892170
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Between-Group Difference in Mean Change in Hemoglobin Concentration | Baseline to Week 12. | Change in hemoglobin concentration from baseline to Week 12, compared between the two randomized treatment groups. |
| Secondary | Change in Serum Ferritin | Baseline to Week 12. | Change in serum ferritin concentration from baseline to Week 12, compared between groups. |
| Secondary | Change in Serum 25-Hydroxyvitamin D. | Baseline to Week 12. | Change in serum 25(OH)D concentration from baseline to Week 12. |
| Secondary | Change in Mean Corpuscular Volume (MCV). | Baseline to Week 12. | Change in MCV from baseline to Week 12. |
| Secondary | Change in Mean Corpuscular Hemoglobin (MCH). | Baseline to Week 12. | Change in MCH from baseline to Week 12. |
| Secondary | Change in Serum Iron. Description | Baseline to Week 12. | Change in serum iron concentration from baseline to Week 12. Unit: µg/dL, if this is the laboratory's reporting unit. |
| Secondary | Change in Total Iron-Binding Capacity (TIBC). | Baseline to Week 12. | Change in TIBC from baseline to Week 12. Unit: Use the laboratory's reporting unit. |
| Secondary | Change in Serum Hepcidin. | Baseline to Week 12. | Change in serum hepcidin concentration from baseline to Week 12. Unit: Assay-dependent. |
| Secondary | Change in hsCRP. | Baseline to Week 12, subject to feasibility. | Change in hsCRP concentration from baseline to Week 12, if measured at both visits. |
| Secondary | Resolution of Anemia. | Week 12. | Proportion of participants meeting the prespecified hemoglobin criterion for anemia resolution at Week 12. |
| Secondary | Adherence to Supplementation. | Weeks 2, 4, 8, and 12. | Adherence to the assigned iron and vitamin D supplementation regimen, assessed using the prespecified adherence method. |
| Secondary | Incidence of Adverse Events. | Weeks 2, 4, 8, and 12. | Proportion of participants experiencing adverse events, including gastrointestinal symptoms, during supplementation. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07892170/registered